The latest research on the effect of gefitinib in the progression of lung adenocarcinoma (LUAD) discovered that a risk model constructed around its target genes FBP1, SBK1, and AURKA was associated with a poor prognosis and was strongly connected to the immune microenvironment [38], although the exact mechanism remains unclear. This evidence concerns the gene FBP1 and lung adenocarcinoma.